Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Osteoporosis: HELP
Articles by Maria L. Brandi
Based on 3 articles published since 2010
(Why 3 articles?)
||||

Between 2010 and 2020, Maria L. Brandi wrote the following 3 articles about Osteoporosis.
 
+ Citations + Abstracts
1 Clinical Trial 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. 2017

Bone, Henry G / Wagman, Rachel B / Brandi, Maria L / Brown, Jacques P / Chapurlat, Roland / Cummings, Steven R / Czerwiński, Edward / Fahrleitner-Pammer, Astrid / Kendler, David L / Lippuner, Kurt / Reginster, Jean-Yves / Roux, Christian / Malouf, Jorge / Bradley, Michelle N / Daizadeh, Nadia S / Wang, Andrea / Dakin, Paula / Pannacciulli, Nicola / Dempster, David W / Papapoulos, Socrates. ·Michigan Bone and Mineral Clinic, Detroit, MI, USA; Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Harbor, MI, USA. Electronic address: hgbone.md@att.net. · Research and Development, Amgen, Thousand Oaks, CA, USA. · Department of Surgery and Translational Medicine, University of Florence, Florence, Italy. · Department of Medicine, Laval University and CHU de Québec Research Centre, Quebec City, QC, Canada. · INSERM UMR 1033, Université de Lyon, Hôpital Edouard Herriot, Lyon, France. · San Francisco Coordinating Center, CPMC Research Institute, UCSF, San Francisco, CA, USA. · Krakow Medical Centre, Krakow, Poland. · Department of Endocrinology and Metabolism, Medical University Graz, Graz, Austria. · Department of Medicine, Division of Endocrinology, University of British Columbia, Vancouver, BC, Canada. · Department of Osteoporosis, Bern University Hospital, Bern, Switzerland. · Bone and Cartilage Metabolism Unit, University of Liège, Liège, Belgium. · Department of Rheumatology, Paris Descartes University, Paris, France. · Department of Internal Medicine, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. · Department of Pathology and Cell Biology, Columbia University, New York, NY, USA; Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, USA. · Center for Bone Quality, Leiden University Medical Center, Leiden, Netherlands. ·Lancet Diabetes Endocrinol · Pubmed #28546097.

ABSTRACT: BACKGROUND: Long-term safety and efficacy of osteoporosis treatment are important because of the chronic nature of the disease. We aimed to assess the long-term safety and efficacy of denosumab, which is widely used for the treatment of postmenopausal women with osteoporosis. METHODS: In the multicentre, randomised, double-blind, placebo-controlled, phase 3 FREEDOM trial, postmenopausal women aged 60-90 years with osteoporosis were enrolled in 214 centres in North America, Europe, Latin America, and Australasia and were randomly assigned (1:1) to receive 60 mg subcutaneous denosumab or placebo every 6 months for 3 years. All participants who completed the FREEDOM trial without discontinuing treatment or missing more than one dose of investigational product were eligible to enrol in the open-label, 7-year extension, in which all participants received denosumab. The data represent up to 10 years of denosumab exposure for women who received 3 years of denosumab in FREEDOM and continued in the extension (long-term group), and up to 7 years for women who received 3 years of placebo and transitioned to denosumab in the extension (crossover group). The primary outcome was safety monitoring, comprising assessments of adverse event incidence and serious adverse event incidence, changes in safety laboratory analytes (ie, serum chemistry and haematology), and participant incidence of denosumab antibody formation. Secondary outcomes included new vertebral, hip, and non-vertebral fractures as well as bone mineral density (BMD) at the lumbar spine, total hip, femoral neck, and one-third radius. Analyses were done according to the randomised FREEDOM treatment assignments. All participants who received at least one dose of investigational product in FREEDOM or the extension were included in the combined safety analyses. All participants who enrolled in the extension with observed data were included in the efficacy analyses. The FREEDOM trial (NCT00089791) and its extension (NCT00523341) are both registered with ClinicalTrials.gov. FINDINGS: Between Aug 3, 2004, and June 1, 2005, 7808 women were enrolled in the FREEDOM study. 5928 (76%) women were eligible for enrolment in the extension, and of these, 4550 (77%) were enrolled (2343 long-term, 2207 crossover) between Aug 7, 2007, and June 20, 2008. 2626 women (1343 long-term; 1283 crossover) completed the extension. The yearly exposure-adjusted participant incidence of adverse events for all individuals receiving denosumab decreased from 165·3 to 95·9 per 100 participant-years over the course of 10 years. Serious adverse event rates were generally stable over time, varying between 11·5 and 14·4 per 100 participant-years. One atypical femoral fracture occurred in each group during the extension. Seven cases of osteonecrosis of the jaw were reported in the long-term group and six cases in the crossover group. The yearly incidence of new vertebral fractures (ranging from 0·90% to 1·86%) and non-vertebral fractures (ranging from 0·84% to 2·55%) remained low during the extension, similar to rates observed in the denosumab group during the first three years of the FREEDOM study, and lower than rates projected for a virtual long-term placebo cohort. In the long-term group, BMD increased from FREEDOM baseline by 21·7% at the lumbar spine, 9·2% at total hip, 9·0% at femoral neck, and 2·7% at the one-third radius. In the crossover group, BMD increased from extension baseline by 16·5% at the lumbar spine, 7·4% at total hip, 7·1% at femoral neck, and 2·3% at one-third radius. INTERPRETATION: Denosumab treatment for up to 10 years was associated with low rates of adverse events, low fracture incidence compared with that observed during the original trial, and continued increases in BMD without plateau. FUNDING: Amgen.

2 Article Determinants of vitamin D levels in children, adolescents, and young adults with juvenile idiopathic arthritis. 2014

Stagi, Stefano / Bertini, Federico / Cavalli, Loredana / Matucci-Cerinic, Marco / Brandi, Maria L / Falcini, Fernanda. ·From the Health Sciences Department, University of Florence, Anna Meyer Children's University Hospital, Florence; Department of BioMedicine, Section of Rheumatology, Transition Clinic, University of Florence, Florence; and Department of Internal Medicine, Endocrinology Unit, University of Florence, Florence, Italy.S. Stagi, MD, Health Sciences Department, University of Florence, Anna Meyer Children's University Hospital; F. Bertini, MD, Department of BioMedicine, Section of Rheumatology, Transition Clinic, University of Florence; L. Cavalli, MD, Department of Internal Medicine, Endocrinology Unit, University of Florence; M. Matucci-Cerinic, MD, Department of BioMedicine, Section of Rheumatology, Transition Clinic, University of Florence; M.L. Brandi, MD, Department of Internal Medicine, Endocrinology Unit, University of Florence; F. Falcini, MD, Department of BioMedicine, Section of Rheumatology, Transition Clinic, University of Florence. ·J Rheumatol · Pubmed #25086083.

ABSTRACT: OBJECTIVE: Deficiency of 25-hydroxyvitamin D [25(OH)D] is reported to be common in patients with rheumatoid arthritis (RA); data in patients with juvenile idiopathic arthritis (JIA) are inconsistent. We assessed serum 25(OH)D in children, adolescents and young adults with JIA, in order to identify the risk factors for vitamin D deficiency in patients with JIA. METHODS: We evaluated 152 patients with JIA: 115 female, 37 male, mean age 16.2 ± 7.4 yrs; evaluated by onset type, 96 had oligoarticular, 35 polyarticular, 7 systemic, and 14 enthesitis-related arthritis (ERA). Patients were compared with a control group matched for sex and age. All patients and controls underwent laboratory tests of plasma 25(OH)D, parathyroid hormone (PTH), calcium, phosphorus, and bone alkaline phosphatase levels, and dual-energy x-ray absorptiometry examination. RESULTS: Patients with JIA showed significantly reduced 25(OH)D levels compared to controls (p < 0.001), even divided into subtypes (oligoarticular, p < 0.05; polyarticular, p < 0.005; systemic, p < 0.001; ERA, p < 0.005). Patients with active disease and/or frequent relapses had significantly reduced 25(OH)D levels compared to patients with no active disease and no frequent flares (p < 0.005, respectively). Nevertheless, JIA patients had significantly higher PTH levels compared to controls (p < 0.0001). JIA patients with 25(OH)D deficiency showed a significantly lower bone mineral apparent density than those with normal 25(OH)D levels (p < 0.001). CONCLUSION: JIA patients have reduced 25(OH)D and higher PTH values. This may explain at least in part why JIA patients, despite more effective current drugs, do not achieve bone-normal condition over time. JIA patients with more severe disease could require higher supplementation of vitamin D to maintain normal 25(OH)D serum levels. Longterm studies are needed to investigate the relationship between serum 25(OH)D levels and disease activity in JIA.

3 Article Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. 2014

Keaveny, Tony M / McClung, Michael R / Genant, Harry K / Zanchetta, Jose R / Kendler, David / Brown, Jacques P / Goemaere, Stefan / Recknor, Chris / Brandi, Maria L / Eastell, Richard / Kopperdahl, David L / Engelke, Klaus / Fuerst, Thomas / Radcliffe, Hoi-Shen / Libanati, Cesar. ·University of California Berkeley, Berkeley, CA, USA; O.N. Diagnostics, Berkeley, CA, USA. ·J Bone Miner Res · Pubmed #23794225.

ABSTRACT: In the randomized, placebo-controlled FREEDOM study of women aged 60 to 90 years with postmenopausal osteoporosis, treatment with denosumab once every 6 months for 36 months significantly reduced hip and new vertebral fracture risk by 40% and 68%, respectively. To gain further insight into this efficacy, we performed a nonlinear finite element analysis (FEA) of hip and spine quantitative computed tomography (QCT) scans to estimate hip and spine strength in a subset of FREEDOM subjects (n = 48 placebo; n = 51 denosumab) at baseline, 12, 24, and 36 months. We found that, compared with baseline, the finite element estimates of hip strength increased from 12 months (5.3%; p < 0.0001) and through 36 months (8.6%; p < 0.0001) in the denosumab group. For the placebo group, hip strength did not change at 12 months and decreased at 36 months (-5.6%; p < 0.0001). Similar changes were observed at the spine: strength increased by 18.2% at 36 months for the denosumab group (p < 0.0001) and decreased by -4.2% for the placebo group (p = 0.002). At 36 months, hip and spine strength increased for the denosumab group compared with the placebo group by 14.3% (p < 0.0001) and 22.4% (p < 0.0001), respectively. Further analysis of the finite element models indicated that strength associated with the trabecular bone was lost at the hip and spine in the placebo group, whereas strength associated with both the trabecular and cortical bone improved in the denosumab group. In conclusion, treatment with denosumab increased hip and spine strength as estimated by FEA of QCT scans compared with both baseline and placebo owing to positive treatment effects in both the trabecular and cortical bone compartments. These findings provide insight into the mechanism by which denosumab reduces fracture risk for postmenopausal women with osteoporosis.